Life Science Tools Market Report 2025

The life science tools market size has grown rapidly in recent years. It will grow from $176.74 billion in 2024 to $201.37 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth during the historic period can be attributed to the rising prevalence of chronic and infectious diseases, increased production volumes in the pharmaceutical and biotechnology sectors, growing demand for clinical diagnostic testing, expansion in environmental and food safety testing, and higher adoption of automation in laboratory workflows.

The life science tools market size is expected to see rapid growth in the next few years. It will grow to $335.13 billion in 2029 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to the rising demand for tools supporting personalized treatment development, expansion of cell and gene therapy manufacturing capacities, increasing need for high-purity reagents in industrial applications, greater adoption of decentralized diagnostic testing, and growth in biologics and biosimilars production. Major trends during this period include the adoption of cloud-based laboratory data management platforms, a shift toward multi-omics integration in research, utilization of cryo-electron microscopy for high-resolution imaging, customization of laboratory tools for specialized research areas, and growth in lab-on-a-chip and microfluidic applications.

The increasing demand for biopharmaceuticals is anticipated to drive growth in the life science tools market in the coming years. Biopharmaceuticals are medical drugs produced through biotechnology, utilizing biological sources such as living cells or organisms to develop therapies including proteins, antibodies, and vaccines. Their rising demand is largely attributed to their effectiveness in treating complex and chronic diseases that traditional small-molecule drugs cannot sufficiently address. Life science tools support the development and manufacturing of biopharmaceuticals by providing essential technologies for research, analysis, and quality control throughout the drug production process, ensuring precision, efficiency, and regulatory compliance. For example, according to Cardinal Health Inc., a US-based healthcare company, as of January 2022, the US had 33 FDA-approved biosimilar products, with 21 available on the market. By 2023, the number of FDA-approved biosimilars had increased to 40, with 25 commercially available. Thus, the growing demand for biopharmaceuticals is driving expansion in the life science tools market.

Leading companies in the life science tools market are focusing on creating innovative solutions, such as automated sequencing platforms, to improve efficiency, accuracy, and accessibility in genetic analysis, thereby accelerating research and clinical diagnostics. Automated sequencing platforms are advanced systems that perform DNA or RNA sequencing with minimal manual input through robotics and software, increasing throughput, reducing errors, and enabling faster, more reliable genetic research and diagnostics. For instance, in October 2024, Illumina Inc., a US-based biotechnology company, launched the MiSeq i100 series, its fastest and simplest benchtop sequencers designed to make next-generation sequencing more accessible to a broader range of laboratories. The MiSeq i100 and MiSeq i100 Plus Systems offer room-temperature kit storage and shipping, eliminating delays caused by reagent thawing and enabling same-day sample-to-analysis workflows. These platforms deliver rapid sequencing with run times as short as four hours, cost-effective consumables, and user-friendly, push-button workflows suitable for applications in microbiology, infectious disease, and oncology. This development highlights the market’s trend toward efficient, scalable, and easy-to-use sequencing tools that empower both researchers and clinicians.

In July 2025, Bio-Rad Laboratories Inc., a US-based life sciences and clinical diagnostics technology company, acquired Stilla Technologies for an undisclosed sum. Through this acquisition, Bio-Rad aims to strengthen its presence in the biotechnology sector by incorporating Stilla’s next-generation digital PCR systems, consumables, and assays into its offerings, enhancing its capabilities in oncology diagnostics, cell and gene therapy, and infectious disease testing across both research and clinical settings. Stilla Technologies SA, based in France, specializes in digital PCR instruments and molecular diagnostic solutions.

Major players in the life science tools market are F. Hoffmann-La Roche Ltd., Merck KGaA, Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies Inc., Lonza Group Ltd., Illumina Inc., Sartorius AG, Shimadzu Corporation, Revvity Inc., Waters Corporation, Bio-Rad Laboratories Inc., Bruker Corporation, Eppendorf AG, Tecan Group Ltd., Bio-Techne Corporation, Takara Bio Inc., GenScript Biotech Corporation, 10x Genomics Inc., and Hamilton Company.

North America was the largest region in the life science tools market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in life science tools market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the life science tools market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The fast surge in U.S. tariffs and the trade tensions that followed in spring 2025 are heavily affecting the medical equipment sector, particularly for imported imaging machine components, surgical-grade stainless steel, and plastic disposables. Hospitals and clinics resist price hikes, pressuring manufacturers’ margins. Regulatory hurdles compound the problem, as tariff-related supplier changes often require re-certification of devices, delaying time-to-market. Companies are mitigating risks by dual-sourcing critical parts, expanding domestic production of commoditized items, and accelerating R&D in cost-efficient materials.

Life science tools are specialized resources and systems designed to support the study, investigation, and understanding of living organisms and their biological processes. They are vital for enabling researchers to obtain accurate and reliable data, which is essential for analyzing and interpreting various aspects of life sciences. By providing the means to explore complex biological mechanisms, these tools are a fundamental component of scientific research and the advancement of knowledge in life sciences.

The primary categories of life science tools include instruments, consumables, and services. Instruments are critical laboratory devices used to analyze biological samples and conduct precise scientific experiments. They employ a variety of technologies, such as polymerase chain reaction (PCR) and quantitative PCR (qPCR), Sanger sequencing, separation technologies, flow cytometry, nucleic acid microarrays, mass spectrometry, and more. These tools find applications in drug discovery and development, clinical diagnostics, genomic and proteomic research, cell biology research, and other areas, serving multiple end users, including academic and research institutions, biotechnology and pharmaceutical companies, hospitals and diagnostic laboratories, contract research organizations (CROs), and government and regulatory agencies.

The life science tools market research report is one of a series of new reports that provides life science tools market statistics, including life science tools industry global market size, regional shares, competitors with the life science tools market share, life science tools market segments, market trends, and opportunities, and any further data you may need to thrive in the life science tools industry. This life science tools market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The life science tools market consists of revenues earned by entities by providing services such as laboratory testing and analysis, bioprocessing equipment supply, clinical trial support services, and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. The life science tools market also includes sales of western blotting, bioreactors, centrifuges, and microfluidics and lab-on-a-chip devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.